^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Diffuse Large B Cell Lymphoma
    Drug Class:T-lymphocyte cell therapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Clin Cancer Res
    Title:

    CD19-Specific CAR-T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor is Effective in Patients with PD-L1 Positive B-Cell Lymphoma

    Published date:
    10/07/2020
    Excerpt:
    Among total of 17 adult patients with R/R lymphoma received the CAR-T therapy, 10 patients had objective response (58.8%), including 7 patients with complete remission (41.2%)….This first-in-human study demonstrates the tolerability, safety, and encouraging efficacy of CD19-PD-1/CD28-CART in PD-L1+ large B-cell lymphoma.
    DOI:
    10.1158/1078-0432.CCR-20-1457